Odyssey Therapeutics (NASDAQ:ODTX) Issues Quarterly Earnings Results, Beats Estimates By $1,000.31 EPS

Odyssey Therapeutics (NASDAQ:ODTX) announced its earnings results on Wednesday. The company reported $999.00 EPS for the quarter, topping the consensus estimate of ($1.31) by $1,000.31, reports.

Odyssey Therapeutics Price Performance

Shares of ODTX stock opened at $18.48 on Thursday. Odyssey Therapeutics has a one year low of $15.35 and a one year high of $20.30.

Insider Transactions at Odyssey Therapeutics

In other news, Director Shelley Chu purchased 11,111 shares of the business’s stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the purchase, the director directly owned 11,111 shares in the company, valued at $199,998. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the business’s stock in a transaction on Friday, May 8th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the purchase, the director owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. The trade was a 50.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 4,183,777 shares of company stock valued at $75,319,986.

Analyst Ratings Changes

ODTX has been the subject of several recent research reports. Wall Street Zen upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Oppenheimer assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $40.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating for the company. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating for the company. Finally, Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.